Representativeness in randomised clinical trials supporting acute coronary syndrome guidelines
Poster presentation Sample Work
Who were acute coronary syndrome guidelines tested on?
Clinical practice guidelines for acute coronary syndrome (ACS) shape decisions on diagnosis, reperfusion, antithrombotic therapy and secondary prevention worldwide, and their strongest recommendations rest largely on randomised clinical trials (RCTs). A recommendation is only as applicable as the trial populations behind it. The poster's Background panel makes this point and cites earlier work showing that ACS trials have historically under-represented women, older people and non-white populations, with recruitment concentrated in North America and Europe.
This sample poster examines whether that imbalance persists in the trials cited by current guidelines. Its objective is to evaluate the representativeness of RCTs cited in American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology (ESC) ACS guidelines with respect to geography, patient characteristics, interventions and outcomes. It is written for cardiologists, guideline developers, trialists and researchers interested in health equity and evidence appraisal.
A meta-research design built on guideline citations
Rather than reporting a new trial, the poster studies the evidence base itself, an approach known as meta-research. The Material & Methods panel describes screening four guidelines (two ACC/AHA and two ESC) for primary RCTs cited in support of recommendations, then extracting data at both trial and patient level: recruitment regions, ACS type, baseline characteristics, exclusion criteria, reperfusion and invasive therapy, and clinical outcomes.
Each recommendation was also classified by the guidelines' own grading systems. Class (I to III) expresses the strength of a recommendation, from "is recommended" to "is not recommended", while level of evidence (A to C) reflects the quality and quantity of supporting data, with level A generally requiring multiple RCTs or meta-analyses. Linking trial characteristics to these grades lets the authors ask whether the strongest recommendations rest on the least representative populations. Analyses were descriptive, using percentages and means, with χ² tests for comparisons.
Reading the headline figures, including regions that exceed 100%
The Results panel opens with the scale of the evidence: of 2,128 references in the four guidelines, 407 (19.1%) were primary RCTs, together enrolling 1,582,039 patients (728,605 in control arms and 853,434 in intervention arms). The regional figures need careful reading. Trials recruited in North America (52.6%) and Europe (73.2%) far more often than in Asia (25.3%), Latin America (20.4%), Australia (19.9%) or Africa (12.8%). These percentages sum to more than 100% because they describe the proportion of trials recruiting in each region, and multinational trials count towards several regions.
Other findings concern relevance to the guideline population. Only 68.6% of cited RCTs enrolled ACS patients, and 19.6% actively excluded them. Control-arm participants had a mean age of 62.1 years, 29.9% were women and 80.7% were white. Percutaneous coronary intervention was performed in 42.7% of control patients, and patients with ST-elevation myocardial infarction more often received fibrinolysis than primary PCI (3.3-fold). All-cause mortality ranged from 4.7% within 72 hours to 11.9% between one month and one year. The conclusion summarises geographic and demographic imbalance and lower representation of modern interventions.
The six-panel results figure and what each panel compares
Below the results text, a composite figure supports the main claims:
- Panel A is a colour-coded world map of patient recruitment across guidelines, making the North American and European concentration visible at a glance.
- Panels B to E are grouped bar charts comparing recruitment from Europe and North America by class of recommendation and level of evidence, separately for ESC and ACC/AHA guidelines.
- Further panels show the percentage of RCTs including STEMI and non-ST-elevation ACS patients by guideline, the proportion and type of ACS patients by recommendation, and the percentage of trials without ACS patients by recommendation type.
The map is the most legible element at poster distance; the smaller bar panels reward closer reading. Authors adapting this design should note that the results text refers to a Table 2 carried over from a fuller report. On a poster, any cross-referenced table should either appear on the board or be removed from the text so that viewers are not sent looking for it.
Presenting generalisability findings without overreaching
Meta-research findings can be misread as a verdict that guidelines are wrong. This poster avoids that by concluding that the imbalances underscore the importance of critical appraisal when applying recommendations, which is a measured claim the data support. Older trial populations, for example, reflect the era in which landmark ACS trials were run, when fibrinolysis was more common than primary PCI; the finding is a prompt to consider applicability, not a dismissal of the evidence.
Researchers preparing similar work can use the sample's structure: a clear objective, a transparent screening process, descriptive statistics matched to the question, and a conclusion framed around appraisal. Pubrica's poster preparation service supports layout and figure design for evidence-synthesis posters, clinical literature reviews for evidence-based medicine address how trial evidence applies in practice, and meta-analysis support covers projects that go on to pool trial data quantitatively.
Questions about this sample
Why do the regional recruitment percentages add up to more than 100%?
Each percentage gives the share of the 407 trials that recruited at least some patients in that region. Many ACS trials are multinational, so one trial can count towards North America, Europe and Asia at once. The figures therefore describe how widely regions were involved, not how the total patient population was divided.
What do class and level of evidence mean in the poster's analysis?
They are the grading systems used by ACC/AHA and ESC guidelines. Class (I to III) indicates how strongly an intervention is recommended or advised against, and level of evidence (A to C) indicates the quality and quantity of supporting data. The poster links trial representativeness to these grades.
Why does the poster note that some cited trials excluded ACS patients?
Guidelines sometimes cite trials from related populations, such as stable coronary disease, to support ACS recommendations. The poster found that only 68.6% of cited RCTs enrolled ACS patients and 19.6% actively excluded them, which raises questions about how directly some evidence applies to people presenting with ACS.
Does the poster suggest clinicians should disregard ACS guidelines?
No. Its conclusion is that geographic and demographic imbalances, and lower representation of modern interventions, call for critical appraisal when applying recommendations to individual patients, particularly those from groups that were under-represented in the underlying trials. It does not argue that the recommendations themselves are invalid.
Give yourself the academic edge today
Each order includes
- On-time delivery or your money back
- A fully qualified writer in your subject
- In-depth proofreading by our Quality Control Team
- 100% confidentiality, the work is never re-sold or published
- Standard 7-day amendment period
- A paper written to the standard ordered
- A detailed plagiarism report
- A comprehensive quality report
Enquire Now
